Target type: biologicalprocess
Any process which produces a purine nucleotide from derivatives of it, without de novo synthesis. [GOC:jp]
Purine nucleotide salvage is a crucial metabolic pathway that allows cells to recycle pre-existing purine bases (adenine and guanine) and their nucleosides (adenosine and guanosine) back into usable nucleotides, thereby conserving energy and resources. This pathway is essential for maintaining adequate nucleotide pools for DNA and RNA synthesis, as well as for other cellular processes. The salvage pathway operates in two main stages:
1. **Base Salvage:**
- **Adenine Phosphoribosyltransferase (APRT)**: This enzyme catalyzes the conversion of adenine to AMP using phosphoribosyl pyrophosphate (PRPP) as the donor of the ribose-5-phosphate moiety.
- **Hypoxanthine-guanine phosphoribosyltransferase (HGPRT)**: This enzyme plays a key role in salvaging both hypoxanthine and guanine. It uses PRPP to convert hypoxanthine to IMP (inosine monophosphate) and guanine to GMP (guanosine monophosphate).
2. **Nucleoside Salvage:**
- **Adenosine Kinase:** This enzyme phosphorylates adenosine to AMP.
- **Guanosine Kinase:** This enzyme phosphorylates guanosine to GMP.
**Steps involved in Purine Nucleotide Salvage:**
1. **Pre-existing Purine Bases and Nucleosides:** Cells obtain pre-existing purines from various sources, including the breakdown of nucleic acids, dietary sources, and the de novo synthesis pathway.
2. **Phosphorylation of Bases:** The salvage pathway begins with the phosphorylation of free purine bases (adenine, guanine, hypoxanthine) to their respective monophosphates (AMP, GMP, IMP) by specific enzymes like APRT and HGPRT.
3. **Phosphorylation of Nucleosides:** If the salvaged purines are in the form of nucleosides (adenosine or guanosine), they are converted to their corresponding monophosphates by specific kinases like adenosine kinase and guanosine kinase.
4. **Conversion to Other Nucleotides:** The salvaged monophosphates (AMP, GMP, IMP) can then be further processed by cellular enzymes to form other purine nucleotides, such as di- and triphosphates (ADP, GDP, ATP, GTP) which are essential for various cellular processes.
**Significance of Purine Nucleotide Salvage:**
- **Energy Conservation:** Salvage pathway saves energy by avoiding the need to synthesize purine nucleotides de novo, which is a more complex and energy-consuming process.
- **Nucleotide Homeostasis:** The salvage pathway helps maintain a balanced pool of purine nucleotides, ensuring the availability of these vital building blocks for DNA and RNA synthesis, as well as other cellular functions.
- **Regulation of Purine Metabolism:** The salvage pathway plays a role in regulating the overall purine metabolism by providing an alternative route for nucleotide production, thereby influencing the de novo synthesis pathway.
**Clinical Relevance of Purine Salvage Pathway:**
- **Defects in Salvage Pathway:** Deficiencies in specific enzymes involved in the salvage pathway can lead to genetic disorders, such as Lesch-Nyhan syndrome, which is characterized by hyperuricemia, neurological abnormalities, and self-injurious behavior.
- **Drug Targets:** Enzymes involved in purine salvage have been targeted for drug development, particularly in the treatment of various diseases, including cancer and autoimmune disorders.'
"
Protein | Definition | Taxonomy |
---|---|---|
Adenosine deaminase | An adenosine deaminase that is encoded in the genome of human. [PRO:DNx, UniProtKB:P00813] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
9-(2-hydroxy-3-nonyl)adenine | 9-(2-hydroxy-3-nonyl)adenine: specific inhibitor of adenosine deaminase | ||
coformycin | coformycins | EC 3.5.4.4 (adenosine deaminase) inhibitor | |
adenosine | quinquefolan B: isolated from roots of Panax quinquefolium L.; RN not in Chemline 10/87; RN from Toxlit | adenosines; purines D-ribonucleoside | analgesic; anti-arrhythmia drug; fundamental metabolite; human metabolite; vasodilator agent |
nebularine | nebularine : A purine ribonucleoside that is 9H-purine attached to a beta-D-ribofuranosyl residue at position 9 via a glycosidic (N-glycosyl) linkage. nebularine: structure | purine ribonucleoside; purines D-ribonucleoside | fungal metabolite |
9-(2-hydroxy-3-nonyl)adenine | (2R,3S)-EHNA : EHNA of absolute configuration 2R,3S. Selective inhibitor of cGMP-stimulated phosphodiesterase (PDE2) (IC50 = 0.8 - 4 mM). Also a potent inhibitor of adenosine deaminase. | EHNA | EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; EC 3.5.4.4 (adenosine deaminase) inhibitor |
9-(2-hydroxy-3-nonyl)adenine | (2S,3R)-EHNA : EHNA of absolute configuration 2S,3R. | EHNA | |
1-deazaadenosine | 1-deazaadenosine: inhibits nucleic acid & protein synthesis; structure given in first source | ||
pentostatin | pentostatin : A member of the class of coformycins that is coformycin in which the hydroxy group at position 2' is replaced with a hydrogen. It is a drug used for the treatment of hairy cell leukaemia. Pentostatin: A potent inhibitor of ADENOSINE DEAMINASE. The drug induces APOPTOSIS of LYMPHOCYTES, and is used in the treatment of many lymphoproliferative malignancies, particularly HAIRY CELL LEUKEMIA. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity. | coformycins | antimetabolite; antineoplastic agent; Aspergillus metabolite; bacterial metabolite; EC 3.5.4.4 (adenosine deaminase) inhibitor |
8-azanebularine | 8-azanebularine: structure in first source | ||
msh, 4-nle-7-phe-alpha- | polypeptide | dermatologic drug |